In this study, the serum levels of miR-338-3p, COMP, and CS-846 were detected in the patients with KOA and healthy controls, to explore the value of miR-338-3p, COMP, and CS-846 in the early diagnosis of KOA.
Real-time PCR was carried out to evaluate the level of miR-338-3p in KOA patients and healthy controls. Spearman's correlation coefficient was performed to examine the correlation between the expression of miR-338-3p, COMP, and CS-846. Receiver operating characteristic (ROC) curves were carried out to evaluate the diagnostic values of miR-338-3p, COMP, and CS-846 for KOA patients.
In the current study, we first demonstrated that serum miR-338-3p, COMP, and CS-846 levels were increased in KOA patients compared to healthy controls. Moreover, the increase of miR-338-3p, COMP, and CS-846 levels positively correlated with VAS scores and joint space narrowing, suggesting miR-338-3p positively correlated with comprehensive disease severity. In addition, miR-338-3p, COMP, and CS-846 could be used as an independent biomarker for KOA patients. More importantly, combined use of miR-338-3p, COMP, and CS-846 demonstrates a higher diagnostic value with an AUC 0.926 for KOA patients.
The combination of miR-338-3p, COMP, and CS-846 demonstrated higher diagnostic value for KOA patients, indicating their combination as novel and promising biomarkers for diagnosis and disease severity of KOA.